



**unique**

UNDERSTANDING GENES  
& CHROMOSOMES



# UNIQUE

## 2024-2025

# ANNUAL REPORT

Rare Chromosome Disorder Support Group  
trading as Unique  
Company no. 05460413  
Charity no. 1110661  
Year end 31<sup>st</sup> March 2025

## Reference and administrative details

Company number: 05460413

Charity number: 1110661

### Address

Registered office and operational address:

F4, The Stables Station Road West Oxted Surrey RH8 9EE

### Website

rarechromo.org

### Trustees

Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows:

Helen Campbell – Trustee

Isobel Hindle, Trustee, until 3<sup>rd</sup> September 2024

Cecely Hugh – Trustee, appointed 16<sup>th</sup> December 2024

Edna Knight, MBE – Trustee, Founder, Life President

James Lucas – Trustee, appointed 14<sup>th</sup> January 2025

Dr Shwetha Ramachandrappa – Trustee

Sophie Sainty – Chair

Benjamin Stern – Trustee

Fiona Catherine Fulton de Zoete – Trustee

### Staff

Chief Executive Officer: Dr Sarah Wynn

Chief Operating Officer: Craig Mitchell (until 31<sup>st</sup> January 2025)

Information Officer (Family Support): Anita Davis

Information Officer (Family Support): Charlotte Wilmhurst

Information Officer (Family Support): Francesca Wicks

Scientific Communications Officer: Anna Pelling

Scientific Communications Officer: Claire Andersen

Administration Officer: Gemma Mitchell

Finance Officer: Louise Jeffree

Company secretary (until 21<sup>st</sup> November 2024): Craig Mitchell

Company secretary (from 21<sup>st</sup> November 2024): Louise Jeffree

### Patrons

Baroness Pauline Neville-Jones, UK

Professor Albert Schinzel, Switzerland

Professor Dian Donnai, UK

Professor Jean-Pierre Fryns, Belgium

Professor Judith Hall, Canada

### Bankers

Charities Aid Foundation Kings Hill, West Malling, Kent, ME19 4TA

Lloyds Bank, PO Box 545, Faryners House, 25 Monument Street, London, EC3R 8BQ

United Trust Bank, 1 Ropemaker Street, London, EC2Y 9AW

Yorkshire Building Society, Yorkshire House, Yorkshire Drive, Bradford, BD5 8LJ

Virgin Money plc, Jubilee House, Gosforth, Newcastle-upon-Tyne, NE3 4PL

### Independent examiners

Godfrey Wilson Limited, Chartered accountants and statutory auditors 5<sup>th</sup> Floor,  
Mariner House, 62 Prince Street, Bristol, BS1 4QD

**1 in every 150  
babies born  
has a rare  
chromosome  
or gene  
disorder**

There can be significant variation in the impact of having a rare chromosome or gene disorder. They are lifelong genetic conditions which for some people can cause severe learning and physical disabilities, complex medical issues and may be life limiting and life threatening. Others may be more mildly affected or may not be aware they have a condition until they experience difficulties having a family.

The Rare Chromosome Disorder Support group (known as 'Unique') is the only support group for all rare chromosome and gene disorders. UK based with an international reach, we understand genes and chromosomes, and we work with everyone whose life has been touched by rare chromosome or gene disorders. Whether you're someone living with a condition, a parent or carer, an educator, a social worker, a doctor or a scientist – whoever you are, Unique is here for you!







## Mission

**Our mission is to inform, support and alleviate the isolation of anyone affected by a rare chromosome or single gene disorder associated with learning disability/developmental delay and to raise public awareness.**

## Aims and objectives

We aim to act as an international group, supporting, informing and networking with anyone affected by a rare chromosome or single gene disorder and with any interested professionals.

### Inform

We aim to provide specialist information relating to many hundreds of different rare chromosome and gene disorders, to inform parents, carers and the professionals working with them.

### Network

We aim to facilitate a network of families across the world living with rare chromosome or gene disorders, bringing them together both in person and virtually for invaluable mutual support. By networking with professionals and the wider public we also aim to increase awareness and understanding of what it's like to live with these disorders.

### Support

We aim to be there for families and individuals, offering a listening ear, an understanding, sympathetic presence to support them when they need us most, often at or just after receiving a diagnosis of a rare chromosome or single gene disorder.





# LETTER FROM CHAIR

**Through sharing knowledge and lived experience, Unique helps families and professionals navigate the world of chromosome and gene disorders**

This year we celebrated the incredible milestone of Unique turning 40 and, as well as looking back at all that we have achieved, we took it as an opportunity to refresh our image. Working with our members, our staff and trustees and our partnership with Havas Life London, we **launched a brand new logo and branding**. We hope you love it as much as we do! Havas Life London also helped us launch our first ever pop song and video as part of Rare Chromo Day 2024. **Touch the Sky** was co-created with our members using their words, images, and videos to highlight their experiences and emotions throughout their journey, and how it feels to be part of this special community.

As always, our work is informed by and all about our members and the families we serve. Almost 2,000 joined us in the last year to grow our total members to over 32,000 families in over 100 different countries. This year we implemented a long-held plan to set up an advisory board made up of Unique members, whose remit is to guide and advise our plans and strategy. We are also in constant dialogue with our broader membership via the 11,300 members of our Facebook cafe, over 1,000 calls and emails to our helpline and our family day events held this year in Manchester and Glasgow. We also undertook an extensive consultation with our members during this important birthday year. This work will be published in a comprehensive report as part of our Rare Chromo Day 2025 activities but we have taken some of the headline results in order to plan our activities for the upcoming year and beyond:

- 48% of survey respondents felt the focus of Unique's work should be offering opportunities for families to come together locally and nationally. We have secured funding for a Family Conference to be held in Birmingham in March 2026, the talks from which will be recorded to enable our overseas members to benefit too. We will also continue our webinar programme building on the first seven that we put on this year.

- Almost half of survey respondents thought a key focus of Unique's work should be offering more support/information to parents of young people/adults. We have secured funding to run a project targeting parents/carers of young people/adults and outputs from this project will be delivered over the next two years.

This coming year and into the future, we will continue to work hard to make sure the voices of those living with rare gene and chromosome conditions are heard. Much of our work involves advocating on behalf of our members and this year we have presented at over 40 conferences and meetings, staff members sit on 23 NHS, policy or research project boards and we have also continued to campaign to ensure that all those affected by rare chromosome and gene disorders are not forgotten and their needs are included in policy and service developments.


Last but not least, thank you to our dedicated staff who support us all by connecting us, answering our questions, writing the guides that help us to better meet the needs of all of us and our families who are affected by rare gene and chromosome conditions.

We are Unique... and so are you. This is a journey we can make together.

**Sophie Sainty**  
Chair of Trustees



# ACHIEVEMENTS AND PERFORMANCE - Unique at a glance



"We love your organisation and want you to know what a light you are to families after diagnosis when no one else knows or understands. Thank you for all you do."

Survey respondent

## Membership

**32,172** total members in our registry

**1,942** new members registered in 2024/25

**120** countries represented in our membership

**9** parents/carers joined our Membership Engagement Committee from all over the UK and overseas (including 1 from USA, South Africa and New Zealand)

## Engagement

**1,500** shares, 6,200 likes of our 'I Support #RareChromoDay' graphic

**2,500+** responses to our consultation

**2** family events attended by over 100 families

**7** webinars hosted with over 500 participants

**400k** views across our website pages

## Helpline

**1,000+** people supported via our helpline

**333** helpline calls taken

**801** emails to the helpline

**90%** found the email helpline helpful

**89%** found the phone helpline helpful\*

**960** families were sent matching details

"Unique have been really supportive in a time when we have no understanding or support from professionals at the beginning of our journey. Without Unique it would have been a lot more difficult to understand and navigate around professional jargon and understanding of terminology."

Survey respondent

"It was yet again a super day and so wonderful to see everyone again. We had a great time."

Event attendee

## Resources

**1270** guides now published

**8** new condition specific guides

**104K+** views across our condition specific guides

**13** academic papers co-authored on

**40** presentations and talks given

**23** advisory groups participated in

\*Unique survey, 2024



# INFORM

**"I used your website when he was 4 and we were searching for a diagnosis. Because and only because of your website did we figure it out and pointed the doctor in the right directions. We will forever be grateful!"**


Survey respondent

Being diagnosed with a rare chromosome or gene disorder can be a terrifying time. Families and individuals are desperate for information but there is often very little available, or what is available is targeted at medical professionals and difficult to understand. Providing accessible, accurate and easy to understand information remains therefore one of our core services. All our guides are developed in partnership with professionals and people with lived experience, they are often a lifeline for families.

**"Unique's information was helpful and powerful to me. It was my first bit of information and touched my soul that there were others!"**

Survey respondent

Survey responses show that 94.5% of respondents find our condition specific guides helpful. 96% of respondents to our professional survey have signposted to the condition specific information guides.



This year we published:

- 8** new condition specific guides
- 47** translations
- 4** guide updates
- 12** minor updates
- 13** additional publications including 'My Chromosome/ Gene Story' booklets and easy reads

Total publications:

- 314** condition specific guides
  - 233** on chromosome disorders
  - 81** on single gene disorders
- 26** 'My chromosome' story guides
- 12** easy read condition specific guides
- 582** translated guides
  - 22** languages

All guides are available to view and download on our website.

# OUR NEW GUIDES

## New Single Gene Disorder guides

- WSS
- CDK13-related disorder
- BBSOAS
- CIMDAG syndrome
- HIST1H1E Syndrome
- Malan syndrome (NFI-related disorder)
- RNU4-2 ReNU syndrome
- Urofacial syndrome

## Updates

- sSMCs
- USP7-related disorder
- 16p13.11 dups update and new QFN
- 2p16.3 (NRXN1) deletions

## My Chromosome/Gene Story booklets

- CDK13-related disorder
- BBSOAS
- WSS
- HIST1H1E syndrome
- Balanced Translocations
- Malan syndrome

## EasyReads

- CDK13-related disorder
- BBSOAS
- WSS
- HIST1H1E syndrome
- 2p16.3 (NRXN1) deletions

## Others

- 45X/46XY (Minor amendment)
- 17p duplications (Back page update with new charity details)

## Minor updates

- Sleep
- Adoption
- Puberty
- Sleep
- Adoption
- Puberty
- Toilet training
- Transition
- Young carers
- Sports Leisure Days Out
- Communication
- Bereavement and Loss

## Translations

### French

- Chromosome X deletions, duplications and single gene disorders
- X inactivation
- Kleefstra syndrome QFN

### Georgian

- CACNA1A-related disorders
- CACNA1C Timothy syndrome Georgian translation
- Trisomy 8 mosaicism
- Trisomy 9 mosaicism
- PACS1-related syndrome
- Ring 22
- STXBP1 disorders
- Wolf-Hirschhorn syndrome (4p16.3 deletions)
- 1q23.3 microdeletions
- Kleefstra syndrome QFN
- 2q37 deletion syndrome
- KIF11 associated disorder
- RHOBTB2 syndrome

### German

- sSMCs (translation of updated guide)

### Italian

- After Diagnosis What Happens Next overseas edition

### Russian

- 19p13.3 microdeletions
- 19p13.12 microdeletions
- 8p interstitial deletions including 8p12
- 20q13.33 deletions
- DYRK1A and 21q22.13 deletion syndrome
- 19p13.2 microdeletions
- 9q deletions including 9q33
- 16p11.2 microduplications
- 16p12.2 deletions
- 19p13.3 microdeletions
- 22q11.2 microduplications
- 3q29 deletions and microdeletions
- BBSOAS
- Mosaicism
- DNA sequencing

### Spanish

- GATA6 syndrome
- ReNU syndrome
- BBSOAS
- BBSOAS My Gene Story
- BBSOAS Easy Read

### Swedish

- Unbalanced translocations
- Triple X
- DNA sequencing
- Planning your next child
- Balanced translocations

### Traditional Chinese

- X inactivation
- X chromosome deletions duplications and single gene disorders

### Simplified Chinese

- X inactivation
- X chromosome deletions duplications and single gene disorders

## Webinars

During the year we hosted **7** webinars with over **500** people attending. Topics have included sleep, speech and language, you and your emotional wellbeing and on the newly discovered RNU4-2/ ReNU syndrome.

Feedback shows participants found these incredibly helpful, for example 90% of attendees at the speech and language webinar said it met or exceeded their expectations and that they would attend another webinar.

- [Living with Rare Chromosome or Gene Disorders: You and Your Emotional Wellbeing, June 2024](#)
- [RNU4-2/ReNU syndrome x3, October 24, November 2024 and January 2025](#)
- [Prof Marianne van den Bree: The Rare Genetic Variant Research Programme at Cardiff University, December 2024](#)
- [Luci Wiggs, Sleep, February 2025](#)
- [Speech and Language webinar with Professor Angela Morgan, September 2024](#)



## How our activities deliver public benefit


The Trustees confirm their due regard for the Charity Commission Guidance on Public Benefit in reviewing Unique's aims, objectives and activities undertaken, planning future strategy and setting policy. As the UK's only charity working in this specific field, throughout this report we have detailed the ways in which we help beneficiaries, providing specialist information as well as softer support.

For the wider public benefit, we continue to ensure there is representation of the public and patient voice in numerous ways. We sit on NHS boards including the NHS Clinical Reference Group for Genomics, the Joint Committee on Genomics in Medicine and the NHS People and Communities Forum. Unique staff also sit on the Scientific Advisory Boards for NIHR Manchester Biomedical Research Centre, DECIPHER and Rare Disease Hong Kong. As clinical care is rapidly evolving to include genetic/genomic testing in almost all areas of medicine, it is vital that our beneficiary group continues to be fully represented and heard. Unique staff reflect the views of our community by inputting into England's Rare Diseases Action Plan, working with the Department of Health and Social Care (DHSC) to continue to help develop the guidance underpinning the Down Syndrome Act and sitting on numerous research project advisory boards. Our staff have also inputted into UK service delivery, for example by providing expert advice in the development of the updated specifications for both the NHS Genomic Medicine Service and the NHS Clinical Genetics Service.



## New projects to increase and develop information guides

Advances in genetic testing in addition to research into the causes of rare conditions has resulted in more people worldwide being diagnosed with rare chromosome and gene disorders. Unique's mission to provide accessible, family friendly information to all those who desperately need it has struggled to keep apace, given our limited resources. This year we have worked hard to build relationships with the professionals who work with rare genetic condition families and who support our information project, but we have also explored other ways to increase production of these much needed resources.



### Collaboration with the Julia Garnham Centre (JGC)

Our collaboration with the JGC (Sheffield Children's Hospital and the University of Sheffield) has continued at a steady pace. Following a Unique presentation at the annual Association of Clinical Genomics Sciences (ACGS), the team from the Julia Garnham Centre made contact to explore the possibility of their interns helping to produce and write Unique information guides. In collaboration we have applied for funding for a pilot project. The grant was successful, and a carefully selected list of conditions have been selected to be considered for guide production and nine students are currently working on these guides.

### Collaboration with Manchester University and Shorthills AI

This project, which has also been successful in securing funding for a pilot project aims to design an Artificial Intelligence (AI) tool to aid with the data and literature steps of the information guide production pathway. We have continued to work extensively on our AI systems project with the teams in Manchester and India and attend fortnightly meetings. Scope/depth/accuracy, readability and plagiarism tools are under development and template adherence details have been modified to avoid AI hallucinations. We are now working with 10 clinical geneticists worldwide to trial the model to produce 10 new guides. We hope to apply for further funding to continue this promising and exciting line of work.



# NETWORK

Networking is an important part of how we advocate for the rare chromosome and gene disorder community. We actively support, promote and participate in research, training and activities that can improve the lives of our community.

We maintain a number of strategic alliances including being members of Eurordis, Breaking Down Barriers and ERN Ithahca. We are also an active member of Genetic Alliance UK collaborating on a 'SARD' (Seeking A Rare Diagnosis), a suite of information materials aimed at supporting individuals and families seeking a diagnosis for genetic/rare conditions, and on working with the Department of Health and Social care (DHSC) to inform the Down Syndrome Act guidance and writing a follow-up letter to the new Health Minister to reiterate our call for the guidance to adequately cover other genetic conditions which have similar needs.

One member of our helpline team attended Equality and Diversity training with Breaking Down Barriers, including 'Walking on Eggshells' and 'From Challenging Conversations to Comfortable Communication' (May). The team also attended a webinar by Dr Ramy Saad about epigenetics.

Rare Disease Research UK (RDRUK) platform for Nucleic Acid Therapies (UPNAT) collaboration: Unique has been asked to help produce an information guide to Nucleic Acid Therapies as part of the RDRUK project. Initial meetings have been held and a skeleton outline of a guide produced.

Genomics AI Network (GAIN) project: Unique has been asked to sit on the PPIE panel for the GAIN project, which will shape how Artificial Intelligence should be used in Genomic Medicine. We presented at the launch event in November and will attend regular meetings in 2025 and 2026.

We also supported the Royal College of Speech and Language Therapists (RCSLT) Mental Health Bill – Committee Stage Briefing in support of Baroness Whitaker's communication amendments and a parliamentary briefing on cousin marriage prepared by the British Society for Genomic Medicine (BSGM).

## Academic papers

**The team was involved in the production of 13 academic papers published.**

The papers explore topics such as the benefits, harms and costs of genomic newborn screening for rare conditions, promoting timely and equitable access to rare disease genomic testing, evaluations of the NHS Genomic Medicine Service, the experiences of parenting a child with a genetic neurodevelopmental disorder and exploring if animations can improve parents understanding of prenatal sequencing.

## Advisory groups

**The Unique team sit on 23 advisory groups.**

They include groups for research on digital interventions for childhood disruptive behaviour and anxiety, delivering genomic sequencing in clinical practice: a patient-centred evaluation of the new NHS, evaluating rapid genomic sequencing for critically ill children, ethical, legal and social issues (ELSI) in rare conditions research and clinical practice, exploring family planning and decision making for people with a visible difference which can be inherited and the SWAN Pathway specification group.

See appendix for a full list of advocacy and research activities.



# SUPPORT

"I could not manage without Unique. Just knowing they are there reduces isolation."

Survey respondent

There are now over  
**35k** members on the  
Unique registry  
representing over **120**  
countries.



**"In the beginning I found the family matching service so helpful, it put us in touch with the specific condition group and that helped so much. Since then the [Unique] Facebook café has been great to get and offer advice through"**

Survey respondent

## Consultation

During 2024/2025 we held an extensive consultation with individuals and families impacted by rare chromosome and gene disorders. Around 70% of survey respondents and all focus group participants were members of Unique. They told us that:

**"I'm grateful as Unique was the first place I found practical information on my daughters genetic disorder. The kind most people can manage. Other than this there is just journal articles."**

Survey respondent

**"Unique are fantastic at supporting parents to make a network and upon early diagnosis unique provide a lot of information to help understand technical terms and terminology."**

Survey respondent

**"We attended quite a few conferences and they were so helpful in helping us have certain genetic testing done and we feel they are always available to help with any concerns and questions or worries we have had .They are a life line to families."**

Survey respondent

## Membership committee

A longstanding plan to create a Membership Engagement Committee (MEC) comprised of Unique members who have been engaged in our work, come from all over the world and have children of different ages with a variety of different conditions was realised this year. Two meetings have been held: the first was in May and the MEC evaluated and tested the Unique members survey and the second was held in September where we asked for feedback on our Rare Chromosome and Gene Disorder Awareness Day and also for views and feedback on the new logo and rebranding. We plan to meet 3-4 times per year.

The message from the consultation was clear, Unique members value the community that we provide and would like more opportunities to meet other families in the future – both online and locally.

**2,154** people completed survey responses

**538** partial responses


**45** focus group participants

**53** feedback group participants

**182** comments on our public Facebook/Instagram

**28** comments in our private Facebook group

**79** professionals survey respondents



# FAMILY DAYS

## GLASGOW



"It was yet again a super day and so wonderful to see everyone again. We had a great time."

Family day attendee



## MANCHESTER




"I loved the opportunity to meet other 'unique' families - we are such a rare bunch! All of my connections since my daughter's diagnosis have been online, so it was really nice to have a chance to connect in person. Thank you for the opportunity!"

Family day attendee




# RARE CHROMOSOME AND GENE DISORDER AWARENESS DAY

Also known as Rare Chromo Day, this awareness day is the focal point of the Unique community bringing together families from around the world to celebrate the achievements of their affected family member. This year it took place on 13<sup>th</sup> June 2024.




## Highlights



The launch of the song 'Touch the Sky' and the accompanying lyrics video, which has to date been viewed almost 3,800 times on our [YouTube channel](#).




A collaboration with Jean-Christophe Novelli on Instagram, liked more than 2,000 times and his wife Michelle's open and honest interview with Sarah.




Holding our first live Q&A session via Zoom, which was attended by more than 30 members.



'I Support Rare Chromo Day' graphic being shared 1,500 times, liked 6,200 times and being seen on screen 119,000 times on Facebook and seen 51,000 time on Instagram.



We took over Genomics England's X account to promote our content to their 30,000 followers.



20 people completing our Unique23 challenge, raising over £15,000.



Lots of members and supporters buying merchandise, wearing blue and yellow and holding assemblies, cakes sales etc at school.





# HELP TO MAKE IT POSSIBLE

## Fundraisers

The 2024/25 financial year was awash with fabulous fundraisers. Our thanks to everyone who threw themselves into cycle challenges, marathon runs, boxing matches, cake sales and our awareness day Unique23 challenge. We receive no government funding so the proceeds from these fundraisers make a huge difference to our work.

**67**

amazing individual fundraisers

**£82k**

raised between them

**3**

companies chose Unique as their Charity of the Year

**£58k**

raised between them

## Our special thanks go to:

- Kat Shaw and over 80 of her colleagues from Accenture who took part in a Who Dares Wins trek through the Peak District over a somewhat chilly weekend in May 2024.
- Catriona Taylor and her colleagues at The Blair Partnership who spent the year raising funds for Unique via so many different events, we lost count and then put them all into a lovely video celebration for their end of year presentation.
- Reece Grundy and his colleagues at Jensten Insurance who also spent the year putting on events and raising funds and awareness of Unique's work.





## Funders

During 2024/25, we were the grateful recipients of over £86,000 in grants from Charitable Foundations and Trusts. Many of these were in response to applications made by us but others were from long standing supporters of our work. Some were restricted for use on specific projects while others were unrestricted for assisting with our core costs. We thank them all for their continued support of Unique's aims.

## Volunteers and Pro Bono Support

We are very grateful to the large number of volunteers who helped during the year. These include hundreds of genetics specialists who give their time freely to write and/or review our condition specific information guides prior to publication. To ensure accuracy, it is our policy that none of our information is published until this independent verification has taken place. After an introduction by Passion Partnership, we are delighted to have entered a two-year pro bono partnership with Havas Life Medicom, a specialist medical communications agency. Their team have worked with great passion and enthusiasm, assisting with our marketing and social media content on Rare Disease Day in February and undertaking a review and consultation process, with an exciting refresh and rebranding of the charity. Creative marketing professional Roberta Elliott has been hugely helpful, creating a variety of assets for use in our social media and other marketing, particularly in relation to our annual awareness day campaign. Roberta donates her time, as does Unique member Simon Jackson, a business analyst who specialises in databases who is helping us with the planning and spec for our planned database upgrade – an extremely significant project for us.

**A huge thank you to all the genetics specialists who helped to translate our guides**



# FINANCIAL REVIEW

## Income

The 2024/25 financial year was a very successful one, with total income for the year coming to 467,192 an increase of 18% on the previous year, thanks largely to a few corporate fundraisers where we were the chosen Charity of the Year. Unrestricted income from all sources amounted to £397,168. This funding is particularly important as it affords the flexibility to direct expenditure to where Trustees feel it can be of most benefit to those who need us. From charitable trusts and foundations, we received unrestricted funding of £24,100 and restricted income of £61,931. This was for costs associated with the planned upgrade of our database, regional family support across the UK including funding for in-person family events in Wales, a Carer of Adults project and published information guides.

## Expenditure

Total expenditure for the year was £402,200 an increase of 8.8%, caused by increased costs for hardware as well as the hire of a consultant with specific experience in the rare disease space to conduct a comprehensive survey of our membership and assist with grant applications. Trustees and senior staff met regularly during the year (in person and via Zoom), monitoring financial performance and our budget. Our robust financial management procedures mean that moving forward we can continue to invest in staff, resources and infrastructure to ensure longer-term sustainability in the face of ever-increasing demand.

## Level of reserves

The Trustees have recently opted to change our reserves policy to hold a minimum reserve equivalent to six months' average operating costs for the previous year. For this year, this equates to not less than £186,648. Trustees have again decided to designate £40,000 to protect our Listening Ear Telephone and Email helpline service. Reserves at the end of the year are £402,794, of which unrestricted reserves

stand at £327,929. Restricted funding carried forward to 25/26 is £74,865. Reserves protect our current and future beneficiaries, safeguarding key services to ensure the charity's future sustainability. Over the coming year, we expect our planned new registry project to come to fruition, meaning levels of reserves will reduce significantly.

## Future Plans

Having conducted a data cleanse of the information currently in our database, we are about to start developing our new registry which will provide Unique with the tools to enhance the service we provide our families for years to come. This has been a longstanding need for Unique, and we are grateful to those who have assisted in the planning stages.

Our recent survey of our membership has highlighted that we need to do more to assist them with the care of their adult family member with an RCGD. In this respect we were successful in applying for a grant from Awards for All England towards a 2-year project which will involve setting up a working group to bring together families of adults with RCGD and co-design new support services to meet their needs. It will include up to 4 regional workshops as well as virtual drop-in-sessions, online information sessions and the setting up of WhatsApp groups. The learning from this project will help us better understand the needs of this section of our community and develop more long-term support for families throughout their journey, not just at the point of diagnosis.

Finally, we have received funding from Jeans for Genes for a Unique Conference being planned for March 2026 in Birmingham. The conference will bring many of our families together to access support and information, develop a network of friends and connections and improve their mental wellbeing.



# STRUCTURE, GOVERNANCE AND MANAGEMENT

Unique is an incorporated charity and company limited by guarantee, governed by a Memorandum and Articles of Association. The charity currently has eight Trustees with diverse backgrounds including law, business, finance, accounting, education and medicine. New Trustees are recruited by advertising as widely as possible, including via our own networks and we operate a fair, transparent and equal opportunity policy for recruitment of Trustees and staff. Trustees are currently undertaking a skills audit of the board of trustees, with the aim of identifying any skills gaps.

Governance and management structures of the charity are regularly reviewed to ensure optimal use of resources. Trustees meet four times per year and also correspond regularly via email and other digital means, taking a proactive approach to any fluctuations in income and refining strategy accordingly.

The Trustees delegate day-to-day management of the charity's activities to Dr. Sarah Wynn, Chief Executive Officer (CEO), together with Louise Jeffree, Company Secretary. Unique currently employs eight members of staff, including the CEO, three of whom are full time and five part-time.

Registered members of the company limited by guarantee and others with an interest in Unique were invited to attend the nineteenth Annual General Meeting which was held in October 2024 and are kept informed by the Company Secretary.

Unique is an equal opportunity employer and take our responsibilities for the welfare of our staff extremely seriously. We contract an external HR provider to ensure our terms and conditions of employment, policies and recruitment processes are fair and transparent

## Management of risk

Unique's Risk Register is reviewed annually and details the major risks to which the charity could be exposed. A disaster recovery plan is

in place, with appropriate contingency plans as operating conditions and/or performance change. The charity's financial and other performance measures are reviewed at each board meeting and at other times as necessary.

## Compliance and Training

Given the importance to our work of personal and sensitive medical data, staff and trustees are aware of the requirements of data protection law and have received training in this area. All Trustees and staff undergo regular DBS checks. Staff performance is kept under ongoing review and all staff have an annual appraisal covering the key responsibilities of their role and how they relate to Unique's charitable aims. Any knowledge/skills gaps or training are identified and appropriate training sourced.

Given that we often receive research proposals from professionals, academics and others who request that we share them with member families, we have an Internal Research and Ethics Committee to appraise them and give approval before sharing.

## Infrastructure

Throughout the year, Trustees and staff continued to ensure Unique's infrastructure is fit for purpose. We maintain a small office hub, with most staff dividing their time between working from the office and working from home. Data security is paramount, with sensitive medical information stored, accessed and processed by staff according to our data protection policies, with which all staff are expected to familiarise themselves. All data are processed in accordance with the Data Protection Act/the General Data Protection Regulations (GDPR). We contract an expert IT company to provide secure systems including off-site solutions, allowing staff to work securely on a hybrid basis.

# STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also directors of the charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing those financial statements the trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgements and accounting estimates that are reasonable and prudent;
- State whether applicable UK accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements; and
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Members of the charity guarantee to contribute an amount not exceeding £10 to the assets of the charity in the event of winding up. The trustees are members of the charity but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

## Independent examiners

Godfrey Wilson Limited were re-appointed as independent examiners to the charitable company during the year and have expressed their willingness to continue in that capacity.

Approved by the trustees on 16 October 2025 and signed on their behalf by

**Sophie Sainty**  
Chair of Trustees

Company no. 05460413  
Charity no. 1110661

# **Rare Chromosome Disorder Support Group**

## **Report and Unaudited Financial Statements**

**31 March 2025**



## **Independent examiner's report**

### **To the trustees of**

#### **Rare Chromosome Disorder Support Group**

---

I report to the trustees on my examination of the accounts of Rare Chromosome Disorder Support Group (the charitable company) for the year ended 31 March 2025, which are set out on pages 23 to 38.

#### **Responsibilities and basis of report**

As the trustees of the charitable company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the charitable company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charitable company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

#### **Independent examiner's statement**

Since the charitable company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales (ICAEW), which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- (1) accounting records were not kept in respect of the charitable company as required by section 386 of the 2006 Act; or
- (2) the accounts do not accord with those records; or
- (3) the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
- (4) the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Date: 16 October 2025

**William Guy Blake ACA**

**Member of the ICAEW**

For and on behalf of:

**Godfrey Wilson Limited**

Chartered accountants and statutory auditors

5th Floor Mariner House

62 Prince Street

Bristol

BS1 4QD

## Rare Chromosome Disorder Support Group

### Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 March 2025

|                                             | Note | Restricted<br>£      | Unrestricted<br>£     | 2025<br>Total<br>£           | 2024<br>Total<br>£    |
|---------------------------------------------|------|----------------------|-----------------------|------------------------------|-----------------------|
| <b>Income from:</b>                         |      |                      |                       |                              |                       |
| Donations and legacies                      | 3    | 9,743                | 378,295               | <b>388,038</b>               | 339,868               |
| Charitable activities:                      |      |                      |                       |                              |                       |
| <i>Family support services</i>              | 4    | 46,731               | -                     | <b>46,731</b>                | 31,205                |
| <i>Information and awareness</i>            | 5    | 13,550               | 11,298                | <b>24,848</b>                | 20,263                |
| Investments                                 |      | -                    | 7,575                 | <b>7,575</b>                 | 5,331                 |
| <b>Total income</b>                         |      | <u>70,024</u>        | <u>397,168</u>        | <u><b>467,192</b></u>        | <u>396,667</u>        |
| <b>Expenditure on:</b>                      |      |                      |                       |                              |                       |
| Raising funds                               |      | -                    | 68,393                | <b>68,393</b>                | 54,922                |
| Charitable activities:                      |      |                      |                       |                              |                       |
| <i>Family support services</i>              |      | 24,367               | 127,715               | <b>152,082</b>               | 155,628               |
| <i>Information and awareness</i>            |      | 7,020                | 174,705               | <b>181,725</b>               | 159,092               |
| <b>Total expenditure</b>                    | 7    | <u>31,387</u>        | <u>370,813</u>        | <u><b>402,200</b></u>        | <u>369,642</u>        |
| Transfer between funds                      |      | <u>(1,614)</u>       | <u>1,614</u>          | <u>-</u>                     | <u>-</u>              |
| <b>Net income and net movement in funds</b> |      | 37,023               | 27,969                | <b>64,992</b>                | 27,025                |
| <b>Reconciliation of funds:</b>             |      |                      |                       |                              |                       |
| Total funds brought forward                 |      | <u>37,842</u>        | <u>299,960</u>        | <u><b>337,802</b></u>        | <u>310,777</u>        |
| <b>Total funds carried forward</b>          |      | <u><u>74,865</u></u> | <u><u>327,929</u></u> | <u><u><b>402,794</b></u></u> | <u><u>337,802</u></u> |

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 17 to the accounts.

## Rare Chromosome Disorder Support Group

### Balance sheet

As at 31 March 2025

|                                             | Note | £              | 2025<br>£      | 2024<br>£ |
|---------------------------------------------|------|----------------|----------------|-----------|
| <b>Fixed assets</b>                         |      |                |                |           |
| Tangible fixed assets                       | 11   |                | <b>2,103</b>   | 2,115     |
| Investments                                 | 12   |                | <b>4,000</b>   | 4,000     |
|                                             |      |                | <b>6,103</b>   | 6,115     |
| <b>Current assets</b>                       |      |                |                |           |
| Stock                                       | 13   | <b>8,288</b>   |                | 2,877     |
| Debtors                                     | 14   | <b>15,619</b>  |                | 19,156    |
| Cash at bank and in hand                    |      | <b>389,984</b> |                | 323,663   |
|                                             |      | <b>413,891</b> |                | 345,696   |
| <b>Creditors: amounts due within 1 year</b> | 15   | <b>17,200</b>  |                | 14,009    |
| <b>Net current assets</b>                   |      |                | <b>396,691</b> | 331,687   |
| <b>Net assets</b>                           | 16   |                | <b>402,794</b> | 337,802   |
| <b>Funds</b>                                | 17   |                |                |           |
| Restricted income funds                     |      |                | <b>74,865</b>  | 37,842    |
| Unrestricted funds:                         |      |                |                |           |
| Designated funds                            |      |                | <b>40,000</b>  | 40,000    |
| General funds                               |      |                | <b>287,929</b> | 259,960   |
| <b>Total charity funds</b>                  |      |                | <b>402,794</b> | 337,802   |

The directors are satisfied that the company is entitled to exemption from the provisions of the Companies Act 2006 (the Act) relating to the audit of the financial statements for the year by virtue of section 477, and that no member or members have requested an audit pursuant to section 476 of the Act.

The directors acknowledge their responsibilities for:

- (i) ensuring that the Company keeps proper accounting records which comply with section 386 of the Act; and
- (ii) preparing financial statements which give a true and fair view of the state of affairs of the Company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of section 393, and which otherwise comply with the requirements of the Act relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved by the trustees on 16 October 2025 and signed on their behalf by

Sophie Sainty - Trustee (Chair)



## Rare Chromosome Disorder Support Group

### Notes to the financial statements

#### For the year ended 31 March 2025

---

#### 1. Accounting policies

##### a) General information and basis of preparation

Rare Chromosome Disorder Support Group is a charitable company limited by guarantee registered in England and Wales. The registered office address is F4, The Stables, Station Road West, Oxted, Surrey, England, RH8 9EE.

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities in preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Rare Chromosome Disorder Support Group meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

##### b) Going concern basis of accounting

The accounts have been prepared on the assumption that the charity is able to continue as a going concern, which the trustees consider appropriate having regard to the current level of unrestricted reserves and having considered the potential impact of the current economic environment in the UK and beyond. There are no material uncertainties about the charity's ability to continue as a going concern.

##### c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from grants, whether 'capital' or 'revenue', is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably.

Income received in advance of provision of an event or contract for services is deferred until criteria for income recognition are met.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

##### d) Donated services and facilities

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item, is probable and the economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), general volunteer time is not recognised.

## Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

---

#### 1. Accounting policies (continued)

##### d) Donated services and facilities (continued)

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

##### e) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity: this is normally upon notification of the interest paid or payable by the bank.

##### f) Funds accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Designated funds are unrestricted funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the charity's work or for specific projects being undertaken by the charity.

##### g) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

##### h) Redundancy costs

Where an employee receives a termination benefit the full cost is recognised at the date the employee is notified.

##### i) Allocation of support and governance costs

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. These costs have been allocated between activities on the following basis, which is an estimate of staff time spent on each activity:

|                           | 2025  | 2024  |
|---------------------------|-------|-------|
| Raising funds             | 13.6% | 9.0%  |
| Family support services   | 37.4% | 52.0% |
| Information and awareness | 49.0% | 39.0% |

##### j) Tangible fixed assets

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

|                    |                       |
|--------------------|-----------------------|
| Computer equipment | 4 years straight line |
|--------------------|-----------------------|

Items of equipment are capitalised where the purchase price exceeds £500.

## Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

---

#### 1. Accounting policies (continued)

##### k) Fixed asset investments

Investments are stated at market value. The statement of financial activities includes any recognised gains or losses on revaluations and disposals during the year.

##### l) Stock

Stock is included at the lower of cost or net realisable value.

##### m) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

##### n) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

##### o) Creditors

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

##### p) Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value.

##### q) Foreign currency

Transactions in foreign currencies are translated at rates prevailing at the date of the transaction. Balances denominated in foreign currencies are translated at the rate of exchange prevailing at the year end.

##### r) Pension costs

The company operates a defined contribution pension scheme for its employees. There are no further liabilities other than that already recognised in the SOFA.

##### s) Operating leases

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged against profits on a straight-line basis over the period of the lease.

##### t) Accounting estimates and key judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.



## Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

#### 1. Accounting policies (continued)

##### t) Accounting estimates and key judgements (continued)

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are depreciation as described in note 1 (j) to the accounts.

#### 2. Prior period comparatives

|                                             | Restricted<br>£ | Unrestricted<br>£ | 2024<br>Total<br>£ |
|---------------------------------------------|-----------------|-------------------|--------------------|
| <b>Income from:</b>                         |                 |                   |                    |
| Donations and legacies                      | 25,779          | 314,089           | 339,868            |
| Charitable activities                       |                 |                   |                    |
| <i>Family support services</i>              | 31,205          | -                 | 31,205             |
| <i>Information and awareness</i>            | 6,125           | 14,138            | 20,263             |
| Investments                                 | -               | 5,331             | 5,331              |
| <b>Total income</b>                         | <b>63,109</b>   | <b>333,558</b>    | <b>396,667</b>     |
| <b>Expenditure on:</b>                      |                 |                   |                    |
| Raising funds                               | -               | 54,922            | 54,922             |
| Charitable activities                       |                 |                   |                    |
| <i>Family support services</i>              | 29,521          | 126,107           | 155,628            |
| <i>Information and awareness</i>            | 12,136          | 146,956           | 159,092            |
| <b>Total expenditure</b>                    | <b>41,657</b>   | <b>327,985</b>    | <b>369,642</b>     |
| <b>Net income and net movement in funds</b> | <b>21,452</b>   | <b>5,573</b>      | <b>27,025</b>      |

## Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

#### 3. Donations and legacies

|                                       | Restricted<br>£ | Unrestricted<br>£ | 2025<br>Total<br>£ |
|---------------------------------------|-----------------|-------------------|--------------------|
| Grants more than £5,000:              |                 |                   |                    |
| Dorothy Hay-Bolton Charitable Trust   | -               | 9,000             | 9,000              |
| Grants £5,000 or less                 | 1,650           | 15,100            | 16,750             |
| Donations from fundraising activities | 8,093           | 198,773           | 206,866            |
| General donations                     | -               | 50,130            | 50,130             |
| Gift aid                              | -               | 42,793            | 42,793             |
| Overseas donations                    | -               | 15,249            | 15,249             |
| Corporate donations                   | -               | 19,398            | 19,398             |
| Gifts in kind                         | -               | 5,000             | 5,000              |
| Legacies                              | -               | 20,800            | 20,800             |
| Give As You Earn (GAYE)               | -               | 1,520             | 1,520              |
| Pyramids                              | -               | 532               | 532                |
|                                       | <u>9,743</u>    | <u>378,295</u>    | <u>388,038</u>     |

#### Prior year comparative

|                                       | Restricted<br>£ | Unrestricted<br>£ | 2024<br>Total<br>£ |
|---------------------------------------|-----------------|-------------------|--------------------|
| Grants more than £5,000:              |                 |                   |                    |
| Bothwell Charitable Trust             | -               | 5,000             | 5,000              |
| D & J Hunter Charitable Trust         | -               | 21,000            | 21,000             |
| Openwork Foundation                   | 15,000          | -                 | 15,000             |
| Postcode Society Trust                | -               | 25,000            | 25,000             |
| Grants £5,000 or less                 | -               | 13,000            | 13,000             |
| Donations from fundraising activities | 4,294           | 148,153           | 152,447            |
| General donations                     | 6,485           | 43,961            | 50,446             |
| Gift aid                              | -               | 24,764            | 24,764             |
| Overseas donations                    | -               | 14,760            | 14,760             |
| Corporate donations                   | -               | 10,230            | 10,230             |
| Gifts in kind                         | -               | 5,225             | 5,225              |
| Legacies                              | -               | 1,000             | 1,000              |
| Give As You Earn (GAYE)               | -               | 1,462             | 1,462              |
| Pyramids                              | -               | 534               | 534                |
|                                       | <u>25,779</u>   | <u>314,089</u>    | <u>339,868</u>     |

## Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

#### 4. Charitable activities: family support services

|                          | Restricted<br>£ | Unrestricted<br>£ | 2025<br>Total<br>£ | 2024<br>Total<br>£ |
|--------------------------|-----------------|-------------------|--------------------|--------------------|
| Grants more than £5,000: |                 |                   |                    |                    |
| Pears Foundation         | -               | -                 | -                  | 8,500              |
| Awards for All           | 35,181          | -                 | 35,181             | 16,330             |
| Grants £5,000 or less    | 11,550          | -                 | 11,550             | 6,375              |
|                          | <u>46,731</u>   | <u>-</u>          | <u>46,731</u>      | <u>31,205</u>      |

All income from charitable activities: family support services in the prior year was restricted.

#### 5. Charitable activities: information and awareness

|                                      | Restricted<br>£ | Unrestricted<br>£ | 2025<br>Total<br>£ |
|--------------------------------------|-----------------|-------------------|--------------------|
| Grants £5,000 or less                | 13,550          | -                 | 13,550             |
| Christmas card and merchandise sales | -               | 8,833             | 8,833              |
| Conference fees                      | -               | 2,177             | 2,177              |
| Other income                         | -               | 288               | 288                |
|                                      | <u>13,550</u>   | <u>11,298</u>     | <u>24,848</u>      |

#### Prior year comparative

|                                      | Restricted<br>£ | Unrestricted<br>£ | 2024<br>Total<br>£ |
|--------------------------------------|-----------------|-------------------|--------------------|
| Grants £5,000 or less                | 6,125           | -                 | 6,125              |
| Christmas card and merchandise sales | -               | 12,716            | 12,716             |
| Conference fees                      | -               | 1,422             | 1,422              |
|                                      | <u>6,125</u>    | <u>14,138</u>     | <u>20,263</u>      |

#### 6. Government grants

No government grants were received during the current or prior year.



## The Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

#### 7. Total expenditure

|                                            | Raising funds<br>£ | Family support<br>£ | Information and<br>awareness<br>£ | Support and<br>governance<br>£ | 2025 Total<br>£ |
|--------------------------------------------|--------------------|---------------------|-----------------------------------|--------------------------------|-----------------|
| Advertising                                | -                  | 800                 | -                                 | -                              | 800             |
| Independent examination and accountancy    | -                  | -                   | -                                 | 2,820                          | 2,820           |
| Computer expenses                          | 1,211              | 2,935               | 4,441                             | 36                             | 8,623           |
| Depreciation                               | 316                | 866                 | 1,158                             | -                              | 2,340           |
| Event costs                                | -                  | 13,078              | -                                 | -                              | 13,078          |
| Insurance                                  | -                  | -                   | -                                 | 1,851                          | 1,851           |
| Office costs and rent                      | 3,162              | 9,066               | 11,361                            | 312                            | 23,901          |
| Postage and distribution                   | 95                 | 1,183               | 8,591                             | -                              | 9,869           |
| Printing and design                        | 443                | 2,474               | 798                               | -                              | 3,715           |
| Professional fees                          | 7,463              | 2,910               | 3,356                             | 3,126                          | 16,855          |
| Project costs                              | -                  | 5,000               | -                                 | -                              | 5,000           |
| Staff costs (note 9)                       | 32,293             | 88,517              | 116,133                           | 47,542                         | 284,485         |
| Stationery                                 | 83                 | 298                 | 428                               | -                              | 809             |
| Subscriptions, licences and charges        | 15,353             | 395                 | 6,338                             | 34                             | 22,120          |
| Training and other staff costs             | 154                | 130                 | 205                               | 625                            | 1,114           |
| Travel and subsistence                     | 6                  | 1,406               | 481                               | 79                             | 1,972           |
| Website and database development           | 124                | 1,945               | 779                               | -                              | 2,848           |
| <b>Sub-total</b>                           | 60,703             | 131,003             | 154,069                           | 56,425                         | 402,200         |
| Allocation of support and governance costs | 7,690              | 21,079              | 27,656                            | (56,425)                       | -               |
| <b>Total expenditure</b>                   | <b>68,393</b>      | <b>152,082</b>      | <b>181,725</b>                    | <b>-</b>                       | <b>402,200</b>  |

Governance costs were £4,671 (2024: £5,028).

## The Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

#### 7. Total expenditure (continued)

##### Prior year comparative

|                                            | Raising funds<br>£ | Family support<br>£ | Information and<br>awareness<br>£ | Support and<br>governance<br>£ | 2024 Total<br>£ |
|--------------------------------------------|--------------------|---------------------|-----------------------------------|--------------------------------|-----------------|
| Independent examination and accountancy    | -                  | -                   | -                                 | 2,640                          | 2,640           |
| Computer expenses                          | 670                | 3,972               | 3,488                             | -                              | 8,130           |
| Depreciation                               | 126                | 729                 | 546                               | -                              | 1,401           |
| Event costs                                | -                  | 9,640               | -                                 | -                              | 9,640           |
| Insurance                                  | -                  | -                   | -                                 | 2,388                          | 2,388           |
| Office costs and rent                      | 2,268              | 12,680              | 8,788                             | 312                            | 24,048          |
| Postage and distribution                   | 126                | 955                 | 8,385                             | -                              | 9,466           |
| Printing and design                        | -                  | 1,932               | -                                 | -                              | 1,932           |
| Professional fees                          | -                  | -                   | -                                 | 1,878                          | 1,878           |
| Project costs                              | -                  | 5,225               | 5,000                             | -                              | 10,225          |
| Staff costs (note 9)                       | 32,716             | 91,942              | 107,528                           | 40,630                         | 272,816         |
| Stationery                                 | 71                 | 500                 | 414                               | -                              | 985             |
| Subscriptions, licences and charges        | 14,598             | 510                 | 5,313                             | 13                             | 20,434          |
| Training and other staff costs             | 18                 | 56                  | 327                               | 30                             | 431             |
| Travel and subsistence                     | 9                  | 1,038               | 273                               | 115                            | 1,435           |
| Website and database development           | -                  | 1,486               | 307                               | -                              | 1,793           |
| <b>Sub-total</b>                           | <b>50,602</b>      | <b>130,665</b>      | <b>140,369</b>                    | <b>48,006</b>                  | <b>369,642</b>  |
| Allocation of support and governance costs | 4,320              | 24,963              | 18,723                            | (48,006)                       | -               |
| <b>Total expenditure</b>                   | <b>54,922</b>      | <b>155,628</b>      | <b>159,092</b>                    | <b>-</b>                       | <b>369,642</b>  |

## Rare Chromosome Disorder Support Group

### Notes to the financial statements

#### For the year ended 31 March 2025

##### 8. Net movement in funds

This is stated after charging:

|                                                 | 2025<br>£    | 2024<br>£    |
|-------------------------------------------------|--------------|--------------|
| Depreciation                                    | 2,340        | 1,401        |
| Trustees' remuneration                          | Nil          | Nil          |
| Trustees' reimbursed expenses                   | Nil          | Nil          |
| Independent examiners' remuneration (excl. VAT) | <u>2,350</u> | <u>2,200</u> |

No trustees were reimbursed for expenses in the current or prior period.

##### 9. Staff costs and numbers

Staff costs were as follows:

|                                     | 2025<br>£      | 2024<br>£      |
|-------------------------------------|----------------|----------------|
| Salaries and wages                  | 232,404        | 232,748        |
| Social security costs               | 14,388         | 16,968         |
| Pension contributions               | 8,610          | 9,239          |
| Redundancy and termination payments | <u>29,083</u>  | <u>13,861</u>  |
|                                     | <u>284,485</u> | <u>272,816</u> |

No employees had a base salary above £60,000 in either the current or prior year. During the year, one employee's total earnings, including redundancy / termination payments were between £70,000 and £80,000.

The key management personnel of the charity comprise the trustees, the Chief Executive and the Chief Operating Officer. The total employee benefits comprising gross wages, employer pension contributions and employer NI contributions received by the charity's key management personnel in the period was £111,866 (2024: £117,172).

During the year, a termination payment totalling £29,083 was paid to an employee (2024: redundancy payments totalling £13,861 were paid to two employees). No amounts were outstanding at year end.

|                              | 2025<br>No. | 2024<br>No. |
|------------------------------|-------------|-------------|
| Average staff head count     | <u>9</u>    | <u>9</u>    |
| Average full time equivalent | <u>6</u>    | <u>6</u>    |

##### 10. Taxation

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

## Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

#### 11. Tangible fixed assets

|                         | Computer<br>equipment<br>£ |
|-------------------------|----------------------------|
| <b>Cost</b>             |                            |
| At 1 April 2024         | 14,344                     |
| Additions               | 2,328                      |
| Disposals               | <u>(3,699)</u>             |
| <b>At 31 March 2025</b> | <b><u>12,973</u></b>       |
| <b>Depreciation</b>     |                            |
| At 1 April 2024         | 12,229                     |
| Charge for the year     | 2,340                      |
| On disposals            | <u>(3,699)</u>             |
| <b>At 31 March 2025</b> | <b><u>10,870</u></b>       |
| <b>Net book value</b>   |                            |
| <b>At 31 March 2025</b> | <b><u>2,103</u></b>        |
| At 31 March 2024        | <u>2,115</u>               |

#### 12. Investments

|                                           | 2025<br>£           | 2024<br>£           |
|-------------------------------------------|---------------------|---------------------|
| <b>At 31 March 2024 and 31 March 2025</b> | <b><u>4,000</u></b> | <b><u>4,000</u></b> |

A Tracey Emin print was donated in 2005. The trustees have no immediate plans to sell the print and consequently it has been reported as a fixed asset investment in the accounts. The trustees are satisfied that the print is carried at an appropriate value at 31 March 2025.

#### 13. Stock

|             | 2025<br>£    | 2024<br>£    |
|-------------|--------------|--------------|
| Merchandise | <u>8,288</u> | <u>2,877</u> |



# Rare Chromosome Disorder Support Group

## Notes to the financial statements

For the year ended 31 March 2025

### 14. Debtors

|                | 2025<br>£     | 2024<br>£     |
|----------------|---------------|---------------|
| Trade debtors  | 152           | 167           |
| Prepayments    | 8,275         | 7,007         |
| Accrued income | 7,192         | 11,982        |
|                | <b>15,619</b> | <b>19,156</b> |

### 15. Creditors : amounts due within 1 year

|                                    | 2025<br>£     | 2024<br>£     |
|------------------------------------|---------------|---------------|
| Trade creditors                    | 3,500         | -             |
| Accruals                           | 7,072         | 5,645         |
| Other taxation and social security | 2,953         | 4,123         |
| Pension creditor                   | 3,675         | 4,241         |
|                                    | <b>17,200</b> | <b>14,009</b> |

### 16. Analysis of net assets between funds

|                                    | Restricted<br>funds<br>£ | Designated<br>funds<br>£ | General<br>funds<br>£ | Total<br>funds<br>£ |
|------------------------------------|--------------------------|--------------------------|-----------------------|---------------------|
| Tangible fixed assets              | -                        | -                        | 2,103                 | 2,103               |
| Investments                        | -                        | -                        | 4,000                 | 4,000               |
| Net current assets                 | 74,865                   | 40,000                   | 281,826               | 396,691             |
| <b>Net assets at 31 March 2025</b> | <b>74,865</b>            | <b>40,000</b>            | <b>287,929</b>        | <b>402,794</b>      |

#### Prior year comparative

|                                    | Restricted<br>funds<br>£ | Designated<br>funds<br>£ | General<br>funds<br>£ | Total<br>funds<br>£ |
|------------------------------------|--------------------------|--------------------------|-----------------------|---------------------|
| Tangible fixed assets              | -                        | -                        | 2,115                 | 2,115               |
| Investments                        | -                        | -                        | 4,000                 | 4,000               |
| Net current assets                 | 37,842                   | 40,000                   | 253,845               | 331,687             |
| <b>Net assets at 31 March 2024</b> | <b>37,842</b>            | <b>40,000</b>            | <b>259,960</b>        | <b>337,802</b>      |

## Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

#### 17. Movements in funds

|                                      | At 1 April<br>2024<br>£ | Income<br>£    | Expenditure<br>£ | Transfers<br>between<br>funds<br>£ | At 31 March<br>2025<br>£ |
|--------------------------------------|-------------------------|----------------|------------------|------------------------------------|--------------------------|
| <b>Restricted funds</b>              |                         |                |                  |                                    |                          |
| Family support services              | 11,629                  | 26,850         | (24,367)         | -                                  | <b>14,112</b>            |
| Information and awareness            | 434                     | 8,550          | (6,984)          | -                                  | <b>2,000</b>             |
| Database project                     | 25,779                  | 13,093         | -                | -                                  | <b>38,872</b>            |
| Hardware grant                       | -                       | 1,650          | (36)             | (1,614)                            | -                        |
| Carers of Adults Outreach<br>Project | -                       | 19,881         | -                | -                                  | <b>19,881</b>            |
| <b>Total restricted funds</b>        | <b>37,842</b>           | <b>70,024</b>  | <b>(31,387)</b>  | <b>(1,614)</b>                     | <b>74,865</b>            |
| <b>Unrestricted funds</b>            |                         |                |                  |                                    |                          |
| <i>Designated funds:</i>             |                         |                |                  |                                    |                          |
| Listening Ear Fund                   | 40,000                  | -              | -                | -                                  | <b>40,000</b>            |
| <i>Total designated funds</i>        | <b>40,000</b>           | <b>-</b>       | <b>-</b>         | <b>-</b>                           | <b>40,000</b>            |
| General funds                        | 259,960                 | 397,168        | (370,813)        | 1,614                              | <b>287,929</b>           |
| <b>Total unrestricted funds</b>      | <b>299,960</b>          | <b>397,168</b> | <b>(370,813)</b> | <b>1,614</b>                       | <b>327,929</b>           |
| <b>Total funds</b>                   | <b>337,802</b>          | <b>467,192</b> | <b>(402,200)</b> | <b>-</b>                           | <b>402,794</b>           |

#### Purposes of restricted funds

##### **Family support services**

This is funding for our frontline services to families such as our Listening Ear telephone and email helpline and Regional Family Days. It includes grants received during the year from a number of funders and other trusts and foundations, kindly helping us to support families in regions across the UK as part of our wider service.

##### **Information and awareness**

These funds are provided by a number of charitable trusts and foundations, helping us to continue to increase our library of 'practical' information guides for families and supporting our work to provide families with specialist information as part of our wider service.

##### **Database project**

The Unique database contains all the precious information that our members have given us about their family's rare chromosome or gene disorder and how they have been affected. It has enabled us to write the existing chromosome disorder guides that have helped so many and to match new members with families with similar conditions. Our existing database is no longer fit for purpose. We have been fundraising for the last couple of years to fund a new database that will have the capability to aid Unique's work for many years to come, and now have sufficient funding to pay for the initial set up costs, data cleansing of the current data and maintenance fee for the first two years. We are in the final stages of planning prior to implementation of the project, so these funds will be spent during the 2025/26 financial year going forward.

## Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

---

#### 17. Movements in funds (continued)

##### Purposes of restricted funds (continued)

###### *Hardware grant*

These were two restricted grants given specifically to be used for the purchase of laptops for staff. A few of our laptops were too old to cope with the recent Windows 11 upgrade, so these grants were timely, much appreciated and enabled us to purchase two new laptops in 2024/25.

###### *Carers of Adults Outreach Project*

This was a grant made in February 2025 by Awards for All - England and is restricted to the use of a two-year project which will support parents of adults with rare chromosome or gene disorders (RCGD). During a recent consultation process, the need for supporting adult carers was identified as a priority. This project involves setting up a working group which will bring together families of adults with RCGD and co-design new support services to meet their needs. It will include up to 4 regional workshops as well as virtual drop-in-sessions, online information sessions and the setting up of WhatsApp groups. The learning from this project will help us better understand the needs of this section of our community and develop more long-term support for families throughout their journey, not just at the point of diagnosis.

##### Purposes of designated funds

###### *Listening Ear Fund*

The trustees have designated £40,000 from general funds to the charity's 'Listening Ear' project. This sum is to ensure that the Unique helpline, a frontline service providing expert response to first-time callers from the UK and around the world, would be staffed appropriately for at least part of each UK working day during each year. The fund will be spent if and when general funds are unavailable to cover the cost of running the service.

##### Transfers between funds

Transfers between funds reflect the capitalisation of expenditure relating to Hardware Grant items during the year.

## Rare Chromosome Disorder Support Group

### Notes to the financial statements

For the year ended 31 March 2025

#### 17. Movements in funds (continued)

##### Prior period comparative

|                                 | At 1 April<br>2023<br>£ | Income<br>£           | Expenditure<br>£        | At 31 March<br>2024<br>£ |
|---------------------------------|-------------------------|-----------------------|-------------------------|--------------------------|
| <b>Restricted funds</b>         |                         |                       |                         |                          |
| Family support services         | 9,945                   | 31,205                | (29,521)                | 11,629                   |
| Information and awareness       | 6,445                   | 6,125                 | (12,136)                | 434                      |
| Database project                | -                       | 25,779                | -                       | 25,779                   |
| <b>Total restricted funds</b>   | <u>16,390</u>           | <u>63,109</u>         | <u>(41,657)</u>         | <u>37,842</u>            |
| <b>Unrestricted funds</b>       |                         |                       |                         |                          |
| <i>Designated funds:</i>        |                         |                       |                         |                          |
| Listening Ear Fund              | <u>40,000</u>           | <u>-</u>              | <u>-</u>                | <u>40,000</u>            |
| <i>Total designated funds</i>   | <u>40,000</u>           | <u>-</u>              | <u>-</u>                | <u>40,000</u>            |
| General funds                   | <u>254,387</u>          | <u>333,558</u>        | <u>(327,985)</u>        | <u>259,960</u>           |
| <b>Total unrestricted funds</b> | <u>294,387</u>          | <u>333,558</u>        | <u>(327,985)</u>        | <u>299,960</u>           |
| <b>Total funds</b>              | <u><u>310,777</u></u>   | <u><u>396,667</u></u> | <u><u>(369,642)</u></u> | <u><u>337,802</u></u>    |

#### 18. Related party transactions

During the year, the charity received donations from trustees, related charitable trusts of the trustees, and key management totalling £6,427 (2024: £1,563). No amounts were outstanding at year end.



# APPENDIX

## Presentations

- #MedComms webinar to talk about our experience of working with a PR agency on a pro bono basis
- Association for Clinical Genomic Science (ACGS) annual meeting in Birmingham
- ESHG/MRCC Dysmorphology conference
- Adelphi Genetics Forum Annual Conference: The promise and challenges of genomics for patients and families affected by rare conditions
- AGNC lunch and learn: Careers outside of Clinical Genetics centres
- AGNC lunch and learn session: Living with a rare genetic condition: the patient and family perspective
- Brocher Foundation workshop in Geneva: Justice and Genomics. Invited to give the opening talk: The Unique experience: Living with a rare chromosome or gene disorder
- Contact presentation on Unique family days
- Education event for non-genetics HCPs working with people with intellectual disability. Presentation: Patient and family perspective – the impact of a diagnosis of a rare chromosome difference. Also facilitated group discussions
- European Society for Human Genetics (ESHG) in Berlin. Invited panel participant at the 3-day conference involving all those working in genetics in UK, Europe and further afield
- Genomic Ambassador Programme
- Genomic Medicine, Mental Health Services & Equity workshop delivered with Dr Nick Bass, UCL
- [Genomics England podcast recording](#): How has a groundbreaking genomic discovery impacted thousands worldwide?
- Genomics workshop presentation, Home Start, East Lancashire
- Imperial MSc Genomic Medicine students
- Implications of genomics results for the family. Lecture to MSc Genomic Medicine students
- Inaugural RDRUK UPNAT Symposium
- JGC in Sheffield
- Leeds Junior Doctors Genetics Team
- Mainstreaming Genomics module talk (online) – Scientist Training Programme (STP) for Genomic Counselling University of Manchester
- NHS Genomic Healthcare Summit. The hopes and challenges of living with a rare chromosome or gene disorder. Also invited to join a small discussion group with Baroness Merron, Parliamentary Under-Secretary of State, DHSC
- Nottingham Local Government Special Needs Teaching Team
- Panel VUS Interpretation workshop, Festival of Genomics, Excel Centre
- Panel: AGNC ethics workshop, Festival of Genomics, Excel Centre
- Presentation to Belfast clinical genetics dept
- Presentation at the Making Progress with Newborn Screening meeting, Oxford
- [Presentation on Data Access](#) to the Global Alliance for Genomic Health (GA4GH)
- Presentation to Junior Doctors in Leeds
- Presentation to North Thames GMS PPIE group – 'Unique & GAIN'
- Rare & Inherited Diseases Network of Excellence Event
- Rare disease Research UK: ELSI 2nd annual meeting
- [Rare Early Onset Lower Urinary Tract \(REOLUT\) Disorders Node panel discussion and conference](#)
- Rareminds podcast about PGT
- RD day talk to an audience of clinicians, patients and patient organisations: More than you can imagine: genomics and rare disease
- Scottish Clinical Scientists: Living with a rare genetic condition: the patient and family perspective
- Sweden Rare Disease Conference
- Teaching Brighton & Sussex Medical School MDM160 course
- The Blair Partnership (where we have been selected as their Charity of the Year)
- Westminster Health Forum Next steps for genomics in the UK

## Unique memberships

- Breaking Down Barriers
- Eurordis
- ERN Ithaca
- Gene People
- Genetic Alliance UK
- Global Genes
- UK Rare Epilepsies Together (UKRET)
- LeDerR (a service improvement programme for people with a learning disability and autistic people) registered stakeholder

## Boards

- DDD Data Access Policy Group
- DECIPHER Data Access Policy Group (DAC)
- England Rare Diseases Action Plans Patient Advisory Group (PAG)
- Eurordis JARDIN Undiagnosed Multistakeholder Task Force
- Joint Committee on Genomics in Medicine
- Manchester Rare Conditions Centre Advisory Board
- NHS GMS People and Communities Forum
- PPV rep on the Genomics Clinical Reference Group (CRG)
- Rareminds Board of Trustees
- Rare Disease UK's Patient Empowerment Group (PEG)
- Scientific Advisory Board, Manchester Biomedical Research Centre (BRC)
- [Adelphi Genetics Forum](#)

## Research project advisory board/ partnerships

- Advisory Group: Equity in Genomics (led by Hannah McInnes-Dean, ARC)
- Advisory Group: Prenatal screening and therapies (led by Dr Melissa Hill, UCL)
- BINGO research project
- Chromosome 6 Project (led by Prof. Conny Ravenswaaij-Arts, Netherlands)
- Co-production in rare genetic disorders: digital interventions for childhood disruptive behaviour and anxiety (led by Dr Jeanne Wolstencroft, ICH)
- Delivering genomic sequencing in clinical practice: a patient-centred evaluation of the new NHS
- DHSC: Other genetic conditions working group
- DHSC: DS Act advisory group
- Midwifery in Genetics and Genomics (MIGG)
- Genomics AI Network (GAIN) project
- Genomic Medicine Service (led by Dr Celine Lewis, Institute of Child Health)
- European Network on ethics in Psychiatric Genetics (ENEPG)
- Evaluating rapid genomic sequencing for critically ill children (led by Dr Melissa Hill, UCL)
- Genomics England Conditions Framework working group (Newborn Genomes Programme)
- Genomics England's Generation Study Evaluation Advisory Group (led by Dr Celine Lewis, UCL)
- Mainstreaming GCs group
- Rare Disease Network of Excellence: Rare and Inherited Disease
- Rare Disease Node: Epigenomics of Rare Diseases Node (led by Siddharth Banka, Manchester)

- Rare Disease Node: Ethical, legal and social issues (ELSI) in rare conditions research and clinical practice (led by Angus Claire, Cardiff, Ramona Moldovan, Manchester and Anneke Lucassen, Oxford)
- Research supervision (led by Kerry Montgomery, University of the West of England, Centre for Appearance Research, VCT Foundation. Exploring family planning and decision making for people with a visible difference which can be inherited.
- SWAN Pathway specification group
- SWAN UK/Genetic Alliance UK task and finish group

## Research project involvement

- Can artificial intelligence and large language models be employed to create patient information guides for rare conditions. Siddharth Banka (Manchester)
- ENRICH study: In collaboration with UCL
- GENROC study (Karen Low, Bristol)
- Networking Support Scheme in the European Joint Programme on Rare Diseases (Netherlands): Evaluated applications and consensus meetings
- PGT-M surveys (Genetic Alliance UK): Unique liaison
- PREGCARE project (University of Oxford, UK): Unique liaison.
- University of Manchester/Shorthills AI project to assess the ability of AI to help generate patient information guides

## Academic and other papers

[ACGS Position Statement on Rare Disease Genomic Testing](#). Submitted to J Med Genetics. Article written by GA4GH: [https://www.ga4gh.org/news\\_item/uncovering-and-overcoming-common-data-sharing-challenges-in-the-rare-disease-landscape/](https://www.ga4gh.org/news_item/uncovering-and-overcoming-common-data-sharing-challenges-in-the-rare-disease-landscape/)

Baple EL, Scott RH, Banka S, Buchanan J, Fish L, Wynn S, Wilkinson D, Ellard S, MacArthur DG, Stark Z. [Exploring the benefits, harms and costs of genomic newborn screening for rare diseases](#). Nat Med. 2024 Jul;30(7):1823-1825. doi: 10.1038/s41591-024-03055-x. PMID: 38898121.

Dr Sarah Wynn, Prof Sian Ellard, Prof Emma Baple and Prof Rob Taylor. [Rare disease genomic testing: promoting timely and equitable access](#). Comment in Bionews 11 November 2024. <https://www.progress.org.uk/rare-disease-genomic-testing-promoting-timely-and-equitable-access/>

Ellard, H., Clarke, A., Wynn, S. et al. [Written communication of whole genome sequencing results in the NHS Genomic Medicine Service: a multi-centre service evaluation](#). Eur J Hum Genet (2024). <https://doi.org/10.1038/s41431-024-01636-5>

Karen J. Low, Georgia Treneman-Evans, Sarah L Wynn, GenROC Study Consortium, Jenny Ingram. [“They don’t know how to live with a child with these conditions, they can’t understand...”](#): The lived experiences of parenting a child with a genetic neurodevelopmental disorder. Health Expectations 2025

[Large-scale evaluation of outcomes following a genetic diagnosis in children with severe developmental disorders](#). Accepted by Genetics in Medicine Open

Low KJ, Watford A, Blair P, Nabney I, Powell J, Wynn SL, Foreman J, Firth H, Ingram J. [Improving the care of children with GENetic Rare disease: Observational Cohort study \(GenROC\)-a study protocol](#). BMJ Open. 2024 May 16;14(5):e085237. doi: 10.1136/bmjopen-2024-085237. PMID: 38760043; PMCID: PMC11103197. <https://bmjopen.bmj.com/content/14/5/e085237.long>

McInnes-Dean H, Mellis R, Daniel M, Walton H, Baple EL, Bertoli M, Fisher J, Gajewska-Knapik K, Holder-Espinasse M, Lafarge C, Leeson-Beevers K, McEwan A, Pandya P, Parker M, Peet S, Roberts L, Sankaran S, Smith A, Tapon D, Wu WH, Wynn SL, Chitty LS, Hill M, Peter M. [‘Something that helped the whole picture’: Experiences of parents offered rapid prenatal exome sequencing in routine clinical care in the English National Health Service](#). Prenat Diagn. 2024 Apr;44(4):465–479. doi: 10.1002/pd.6537. Epub 2024 Mar 5. PMID: 38441167. <https://obgyn.onlinelibrary.wiley.com/doi/10.1002/pd.6537>

Morgan Daniel 1 2, Hannah McInnes-Dean 1 2 3, Wing Han Wu 1 2, Jane Fisher 3, Caroline Lafarge 4, Kerry Leeson-Beevers 5, Celine Lewis 6, Sophie Peet 7, Dagmar Tapon 8, Sarah L Wynn 9, Lyn S Chitty 1 2, Melissa Hill 1 2, Michelle Peter 1 2. [Can an animation improve parents’ knowledge and how does it compare to written information? Development and survey evaluation of an animation for parents about prenatal sequencing](#) (BJOG-24-1057) has been submitted by Morgan Daniel to BJOG: An International Journal of Obstetrics & Gynaecology. <http://doi.org/10.1002/pd.6792>

Perry, J., Bunnik, E., Rietschel, M., Bentzen, H. B., Ingvaldstad Malmgren, C., Pawlak, J., Chaumette, B., Tammimies, K., Bialy, F., Bizzarri, V., Borg, I., Coviello, D., Crepaz-Keay, D., Ivanova, E., McQuillin, A., Mežinska, S., Johansson Soller, M., Suvisaari, J., Watson, M., Wirgenes, K., Wynn, S. L., Schick Tanz, S. (2025). [Unresolved ethical issues of genetic counselling and testing in clinical psychiatry](#). Psychiatric genetics, 35(2), 26–36. <https://doi.org/10.1097/YPG.0000000000000385>

Peter M, Hill M, Fisher J, Daniel M, McInnes-Dean H, Mellis R, Walton H, Lafarge C, Leeson-Beevers K, Peet S, Tapon D, Wynn SL, Chitty LS, Parker M. [Equity and timeliness as factors in the effectiveness of an ethical prenatal sequencing service: reflections from parents and professionals](#). Eur J Hum Genet. 2024 Oct 3. doi: 10.1038/s41431-024-01700-0. Epub ahead of print. PMID: 39362995. <https://www.nature.com/articles/s41431-024-01700-0>


[Press Release for RNU4-2 paper in Nature](#) (Unique are quoted): <https://www.bdi.ox.ac.uk/news/new-discovery-renews-hope-for-thousands-with-neurodevelopment-disorders>





**Year end:** 31<sup>st</sup> March 2025

**Author:** Unique, The Rare Chromosome and  
Gene Disorder Support Group



**unique**

UNDERSTANDING GENES  
& CHROMOSOMES